ERBB2 and neoplasm: On the other hands, at tumor stage III-IV, of total analyzed patient samples (n = 124), each subtypes were distributed as follows; Luminal A (23%, n = 28), Luminal B (28%, n = 35), HER2-enriched (17%, n = 21), Claudin-low (16%, n = 20), Normal-like (5%, n = 6), and Basal-like (11%, n = 14).